β¨ Medicines Act Notices
NEW ZEALAND GAZETTE, No. 145
1 OCTOBER 2009
Medicines Act 1981
Renewal of Provisional Consent to the Distribution of a Medicine
Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicine set out in the Schedule hereto:
Schedule
Product: Thalidomide Pharmion
Active Ingredient: Thalidomide 50mg
Dosage Form: Capsule
New Zealand Sponsor: Douglas Pharmaceuticals Limited
Manufacturer: Penn Pharmaceutical Services Limited, Tredegar, Gwent, United Kingdom
Note: This consent is given subject to the following conditions and is valid to 18 December 2011:
- Thalidomide may only be prescribed by registered medical practitioners as defined in the Health Practitioners Competence Assurance Act 2003 and who are certified as competent by the Medical Council of New Zealand in the scope and practice of internal medicine.
- Douglas Pharmaceuticals Limited will manage the risk management programme relating to the distribution and use of Thalidomide.
Dated this 25th day of September 2009.
MARK RICHARDS, Acting Deputy Director-General, Sector Accountability and Funding Directorate, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go8135
Consent to the Distribution of a New Medicine
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Ibuprofen
Active Ingredient: Ibuprofen 200mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Mylan New Zealand Limited
Manufacturer: Adcock Ingram Limited - A Medreich Group Company, Bangalore, India
Dated this 25th day of September 2009.
MARK RICHARDS, Acting Deputy Director-General, Sector Accountability and Funding Directorate, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go8131
Consent to the Distribution of Changed Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
Product: Aclasta
Active Ingredient: Zoledronic acid 0.05mg/mL
Dosage Form: Solution for infusion
New Zealand Sponsor: Novartis New Zealand Limited
Manufacturer: Novartis Pharma Stein AG, Stein, Switzerland
Product: Kogenate FS
Active Ingredient: Octocog alfa 2000IU
Dosage Form: Powder for injection
New Zealand Sponsor: Bayer New Zealand Limited
Manufacturer: Bayer Corporation, Berkeley, United States of America
Product: Kogenate FS
Active Ingredient: Octocog alfa 250IU
Dosage Form: Powder for injection
New Zealand Sponsor: Bayer New Zealand Limited
Manufacturer: Bayer Corporation, Berkeley, United States of America
Product: Kogenate FS
Active Ingredient: Octocog alfa 500IU
Dosage Form: Powder for injection
Next Page →
β¨ LLM interpretation of page content
π₯ Renewal of Provisional Consent to the Distribution of Thalidomide Pharmion
π₯ Health & Social Welfare25 September 2009
Medicines Act, Provisional Consent, Thalidomide, Distribution
- MARK RICHARDS, Acting Deputy Director-General, Sector Accountability and Funding Directorate, Ministry of Health
π₯ Consent to the Distribution of Ibuprofen
π₯ Health & Social Welfare25 September 2009
Medicines Act, Consent, Ibuprofen, Distribution
- MARK RICHARDS, Acting Deputy Director-General, Sector Accountability and Funding Directorate, Ministry of Health
π₯ Consent to the Distribution of Changed Medicines
π₯ Health & Social Welfare25 September 2009
Medicines Act, Consent, Changed Medicines, Distribution
- MARK RICHARDS, Acting Deputy Director-General, Sector Accountability and Funding Directorate, Ministry of Health
NZ Gazette 2009, No 145